The Malaysian medicine register — in the present tensePublished by Materia
Every medicine in Malaysia, made legible.
The register — every molecule’s makers, market structure, patent status, and registration pathway, in one place. The facts NPRA holds, finally readable, the same for everyone. A neutral reference for anyone weighing entry into the Malaysian market.
Of the 32 molecules tracked most closely, grouped by market structure — a neutral count of makers and patent status. No verdict; just the shape of the register today.
13 generic-open
1 near cliff
17 multi-source
1 not yet registered
Generic-open — off-patent, generics registeredNear cliff — patent expiry within ~24 monthsMulti-source — 10+ registered makersNot yet registered — no NPRA footprint on file
Every route into Malaysia, across all three regulators, by product class — how long it takes and what it asks. One month axis, so the doors compare directly: the fastest clear in weeks, a new biologic takes three years. The facts; the timing for a specific product is in the read.
012mo24mo36mo
Pharma · NPRA (DRGD)
Drugs, OTC, traditional & supplements — NPRA Drug Registration Guidance Document, 6th ed.
Health supplement notification / registration
Generic · small molecule · health supplement
Ingredient & quality dossier · GMP certification (supplement) · Local product registration holder · Notification / registration fees per NPRA schedule; GMP where applicable
3–9 mo
Traditional product registration
Generic · small molecule · traditional
Traditional-use / literature safety dossier · GMP certification (traditional) · Local product registration holder · RM5,000 processing + RM20,000 GMP inspection (foreign site) where applicable
6–12 mo
Health supplement registration (new ingredient)
New · small molecule · health supplement
Safety & quality dossier · Substantiation of claims · GMP certification (supplement) · Local product registration holder · Registration fees per NPRA schedule; GMP where applicable
6–12 mo
Abridged (non-prescription) evaluation
Generic · small molecule · non-prescription
Bioequivalence or bioavailability data · PIC/S GMP certification · Local product registration holder · RM5,000 processing + RM20,000 GMP inspection (foreign site)
9–15 mo
Traditional product registration (new formulation)
New · small molecule · traditional
Safety & quality dossier · Substantiation of claims · GMP certification (traditional) · Local product registration holder · RM5,000 processing + RM20,000 GMP inspection (foreign site) where applicable
9–15 mo
Abridged / generic evaluation
Generic · small molecule · prescription
Bioequivalence study · PIC/S GMP certification · Local product registration holder · RM5,000 processing + RM20,000 GMP inspection (foreign site)
Cosmetics — notification (not registration) under the Guidelines for Control of Cosmetic Products.
Cosmetic notification
Cosmetic product
Local Cosmetic Notification Holder · Product safety / ingredient compliance (ASEAN annexes) · GMP; safety data on file · RM50 per product / variant
1–3 days*
Sources: NPRA Drug Registration Guidance Document (DRGD, 6th ed.); Medical Device Authority — Medical Device Act 2012 (Act 737); NPRA cosmetic notification. Timelines are directional. Common thread: a local holder / representative is required in every regime. Foreign drug sites need PIC/S GMP; foreign device makers need a licensed Authorised Representative.
Find your route.
Tell us what you’re bringing to Malaysia — see the DRGD route, how long it takes and what it asks. Neutral facts; the timing call for a specific molecule is the read.
Pick a product type to see its pathway.
The atlas — Malaysia, state by state.
Where the patients behind every therapeutic door actually are. Prevalence by state against the national line — switch condition below. One layer of many; supply, procurement and access map the same way.
Peninsular Malaysia
East Malaysia (Borneo)
Below national
Above national— national line 18.3%
Diabetes (raised blood glucose) prevalence by state (adults 18+) against the national 18.3% line — highest in Negeri Sembilan (33.2%), lowest in Sabah (9.8%). Source: NHMS 2019 Vol I (NCD), Table 4.2 · adults 18+ · Institute for Public Health, MOH. Boundaries: DOSM open geodata.
Peninsular Malaysia
East Malaysia (Borneo)
Below national
Above national— national line 30%
Hypertension (raised blood pressure) prevalence by state (adults 18+) against the national 30% line — highest in Sarawak (40.5%), lowest in W.P. Putrajaya (24.7%). Source: NHMS 2019 Vol I (NCD), Table 4.5 · adults 18+ · Institute for Public Health, MOH. Boundaries: DOSM open geodata.